214 related articles for article (PubMed ID: 11008200)
1. C-MYC expression in medulloblastoma and its prognostic value.
Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
[TBL] [Abstract][Full Text] [Related]
2. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
4. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
5. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
[TBL] [Abstract][Full Text] [Related]
6. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
7. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
9. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
[TBL] [Abstract][Full Text] [Related]
10. [Risk stratification in medulloblastoma: screening for molecular markers].
Ebinger M; Senf L; Scheurlen W
Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
[TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.
Min HS; Lee YJ; Park K; Cho BK; Park SH
Acta Neuropathol; 2006 Jul; 112(1):13-20. PubMed ID: 16691420
[TBL] [Abstract][Full Text] [Related]
13. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.
Brown HG; Kepner JL; Perlman EJ; Friedman HS; Strother DR; Duffner PK; Kun LE; Goldthwaite PT; Burger PC
J Neuropathol Exp Neurol; 2000 Oct; 59(10):857-65. PubMed ID: 11079775
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
15. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
[TBL] [Abstract][Full Text] [Related]
16. DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system.
Schofield DE; Yunis EJ; Geyer JR; Albright AL; Berger MS; Taylor SR
Cancer; 1992 Mar; 69(5):1307-14. PubMed ID: 1739930
[TBL] [Abstract][Full Text] [Related]
17. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
18. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma.
Bowers DC; Gargan L; Weprin BE; Mulne AF; Elterman RD; Munoz L; Giller CA; Winick NJ
J Neurosurg; 2007 Jul; 107(1 Suppl):5-10. PubMed ID: 17644914
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
20. Gene aberrations in childhood brain tumors.
Kucerová H; Stejskalová E; Vícha A; Tichý M; Chánová M; Sumerauer D; Koutechký J; Eckschlager T
Folia Biol (Praha); 2000; 46(5):187-90. PubMed ID: 11055797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
